Does zopiclone cause QTc (QT interval) prolongation and what precautions are recommended?

Zopiclone and QTc Prolongation

Zopiclone (eszopiclone) does not appear to cause clinically significant QTc prolongation and is not listed among medications requiring routine cardiac monitoring or ECG surveillance.

Evidence Assessment

The provided FDA drug label for zopiclone/eszopiclone 1 contains no warnings, precautions, or adverse event data regarding QTc prolongation or cardiac arrhythmias. The clinical pharmacology sections detail extensive safety monitoring but make no mention of QT interval effects, which would be prominently featured if this were a recognized concern.

The 2023 Canadian Cardiovascular Society guidelines 2 provide comprehensive lists of QTc-prolonging medications, emphasizing the "anti's" (antibiotics, antifungals, antiarrhythmics, antipsychotics/antidepressants, antiemetics, analgesics). Notably, sedative-hypnotics including zopiclone are conspicuously absent from these lists. The guidelines specifically mention that "among CNS medications; stimulants for attention deficit hyperactivity disorder are generally safe" 2, suggesting that if zopiclone posed significant QTc risk, it would have been explicitly mentioned given the guideline's focus on CNS medications.

Clinical Recommendations

For patients prescribed zopiclone:

• No baseline ECG is required unless other risk factors for QTc prolongation exist (electrolyte disturbances, concurrent QTc-prolonging drugs, structural heart disease, elderly female patients) 2

• No routine cardiac monitoring is necessary during zopiclone therapy

• Standard precautions apply if the patient has multiple risk factors for acquired long QT syndrome (aLQTS):

  • Women, elderly patients (>65 years), structural heart disease 2
  • Electrolyte abnormalities (hypokalemia, hypomagnesemia, hypocalcemia) 2
  • Concurrent use of known QTc-prolonging medications
  • Renal or hepatic impairment affecting drug metabolism

Risk Stratification Algorithm

When prescribing zopiclone, assess:

1. Is the patient taking other QTc-prolonging drugs? (macrolides, fluoroquinolones, antipsychotics, methadone, antiarrhythmics) 2

   • If YES: Consider baseline ECG and monitor electrolytes
   • If NO: Proceed without cardiac monitoring

2. Does the patient have ≥2 risk factors? (female sex, age >65, heart disease, electrolyte disturbances, renal/hepatic impairment) 2

   • If YES: Check baseline ECG and electrolytes before adding zopiclone
   • If NO: No cardiac monitoring needed

3. Is QTc >500 ms or increase >60-70 ms from baseline? 2

   • If YES: This indicates high TdP risk—review ALL medications, not specifically zopiclone
   • Consider www.crediblemeds.org for comprehensive drug interaction checking 2

Important Caveats

The risk of TdP increases when QTc exceeds 500 ms or when a drug increases QTc by >60-70 ms 2. However, this threshold applies to known QTc-prolonging agents. The absence of zopiclone from comprehensive QTc medication lists in recent high-quality guidelines [2-2] and FDA labeling [1-1] strongly suggests it is not a significant contributor to QTc prolongation.

Monitor electrolytes and renal function if patients are taking diuretics or have acute/chronic illness, as these factors independently increase QTc prolongation risk regardless of zopiclone use 2.

Avoid polypharmacy with known QTc-prolonging drugs when possible. If a patient on zopiclone requires an antibiotic, choose penicillins or cephalosporins over macrolides or fluoroquinolones 2.